Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06782555 · ClinicalTrials.gov registry record · Phase 1

A Study of Evofosfamide in Combination with Zalifrelimab and Balstilimab

A Phase 1 study of Metastatic Prostate Cancer and Metastatic Pancreatic Cancer, sponsored by ImmunoGenesis.

Recruiting
Registry status
Phase 1
Development phase
71
Enrollment target
1
Study location

NCT06782555 is a Phase 1 study of Metastatic Prostate Cancer and Metastatic Pancreatic Cancer that is actively recruiting participants, run by ImmunoGenesis. The registered enrollment target is 71 participants, below the 185-participant average among 41 other Metastatic Prostate Cancer trials with a reported enrollment target (62% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06782555, a Phase 1 study of Metastatic Prostate Cancer and Metastatic Pancreatic Cancer, is actively recruiting participants, sponsored by ImmunoGenesis.

RECRUITING
Registry status
Phase 1
Development phase
71 participants
Enrollment target
1
Study location

Study Summary

The purpose of this Phase 1/2 study is to test the overall safety, tolerability, and effectiveness of the combination investigational drugs evofosfamide, zalifrelimab, and balstilimab in treating advanced or metastatic castration-resistant prostate cancer, pancreatic cancer, and human papilloma virus (HPV)-negative squamous cell carcinoma of the head and neck (SCCHN).

Conditions Studied

Metastatic Prostate Cancer Metastatic Pancreatic Cancer Metastatic Head-and-neck Squamous-cell Carcinoma

Interventions

  • DRUG Balstilimab
  • DRUG Evofosfamide
  • DRUG Zalifrelimab

Study Locations (1)

Texas

  • MD Anderson Cancer Center - Houston

Trial Details

FieldValue
Enrollment Target 71 participants
Start Date 2025-01-08
Est. Completion 2028-01
Phase Phase 1

Sponsor

ImmunoGenesis

8 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06782555

The ClinicalTrials.gov registry entry for NCT06782555 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 71 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 185-participant average among 41 other Metastatic Prostate Cancer trials with a reported enrollment target (62% lower). The listed sponsor is ImmunoGenesis, which has 8 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Metastatic Prostate Cancer appearing as the primary indexed condition, and to 3 interventions - of which Balstilimab is the first listed.

NCT06782555 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.

Frequently Asked Questions

What is clinical trial NCT06782555 about?

NCT06782555 is a clinical study titled "A Study of Evofosfamide in Combination with Zalifrelimab and Balstilimab". The purpose of this Phase 1/2 study is to test the overall safety, tolerability, and effectiveness of the combination investigational drugs evofosfamide, zalifrelimab, and balstilimab in treating advanced or metastatic castration-resistant prostate cancer, pancreatic cancer, and human papilloma viru...

What is the current status of trial NCT06782555?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 71 participants. The study started on 2025-01-08. Estimated completion is 2028-01.

What conditions does trial NCT06782555 study?

This clinical trial studies the following conditions: Metastatic Prostate Cancer, Metastatic Pancreatic Cancer, Metastatic Head-and-neck Squamous-cell Carcinoma.

What interventions are being tested in trial NCT06782555?

The interventions under investigation include: Balstilimab (DRUG), Evofosfamide (DRUG), Zalifrelimab (DRUG).

Who is sponsoring clinical trial NCT06782555?

This trial is sponsored by ImmunoGenesis, which has 8 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06782555 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Metastatic Prostate Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Metastatic Prostate Cancer

All registered trials for this condition

Metastatic Pancreatic Cancer

All registered trials for this condition

Texas

All trials with a study site in Texas

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.